Status:
COMPLETED
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
Lead Sponsor:
Yale University
Collaborating Sponsors:
Waterbury Hospital
Health Resources and Services Administration (HRSA)
Conditions:
Buprenorphine
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV car...
Eligibility Criteria
Inclusion
- HIV-infected
- Clinical diagnosis of opioid dependence
- Fluent in English or Spanish
- 18 years or older
Exclusion
- Liver function tests (transaminase only) at five times or higher than normal level;
- Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for benzodiazepine abuse or dependence within the past 6 months;
- DSM-IV criteria for alcohol dependence within the past 6 months;
- Actively suicidal;
- Psychiatric impairment that impedes ability to consent (dementia, delusional, actively psychotic);
- Methadone dose exceeding levels allowing for safe transition to buprenorphine;
- Pregnant women and women actively trying to become pregnant;
- Clinical judgment of local site principal investigator that patient is inappropriate
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00798538
Start Date
August 1 2005
End Date
August 1 2010
Last Update
July 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale AIDS Program
New Haven, Connecticut, United States, 06510